Global Search
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to People / Researchers
Anne M. Connolly, MD

Anne M. Connolly, MD

Researcher
Chief
Division of Neurology
Nationwide Children’s Hospital
700 Childrens Drive
Columbus, Ohio, United States

Anne M. Connolly, MD, is the Chief of the Division of Neurology at Nationwide Children’s Hospital, Professor of Pediatrics at The Ohio State University College of Medicine, and a Member of the Center for Gene Therapy in the Abigail Wexner Research Institute. She is an Internationally recognized expert in Pediatric Neuromuscular Disease and Neuroimmunology. Dr. Connolly’s early research examined the relationship between autoantibodies and childhood neurological disorders. She also studied the natural history and effects of treatment of mouse models of Duchenne muscular dystrophy (DMD) and congenital muscular dystrophy (CMD). She has helped develop outcome measures for infants and boys with DMD and has led or been a collaborator in numerous pivotal clinical trials in children with neuromuscular disorders. At Nationwide Children’s, Dr. Connolly leads the Spinal Muscular Atrophy Clinic.

Dr. Connolly has published 104 peer-reviewed articles, 18 invited reviews and chapters and given more than 50 invited lectures. She is an Associate Editor for the Journal of Child Neurology. In addition, she has served as a national thought leader for multiple foundation and government agency efforts to improve outcomes in children with neuromuscular disorders. She is an American Academy of Neurology Fellow, and Member of the Child Neurology Society, the World Muscle Society and the International Child Neurology Society.

 

Representative Publications:

Progress in Treatment and Newborn Screening for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy

Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening: Essential Steps

Baseline Results of the NeuroNEXT Spinal Muscular Atrophy Infant Biomarker Study

Valproate May Improve Strength and Function in Patients With Type III/IV Spinal Muscle Atrophy

Natural History of Infantile-Onset Spinal Muscular Atrophy

 

view profile

Related Content

© 2023 rareLife solutions Inc.